Skip to main content
main-content

Asthma

Asthma

06-12-2018 | Asthma | News | Article

Tralokinumab does not reduce corticosteroid use in patients with severe asthma

Findings from the TROPOS trial indicate that treatment with the interleukin-13-targeted monoclonal antibody tralokinumab does not decrease corticosteroid use among patients with severe uncontrolled asthma.

Source:

Eur Respir J 2018; doi:10.1183/13993003.00948-2018

01-11-2018 | Asthma | News | Article

COLUMBA results support long-term use of mepolizumab in patients with severe asthma

The anti-interleukin-5 monoclonal antibody mepolizumab has durable safety and efficacy profiles over an average 3.5 years of follow-up in patients with severe eosinophilic asthma, indicate findings from the COLUMBA open-label extension study.

Source:

J Allergy Clin Immunol 2018; doi:10.1016/j.jaci.2018.09.033

11-10-2018 | Asthma | News | Article

Changing inhaler device does not compromise asthma treatment effectiveness

Results of a real-world study suggest that changing from a dry powder inhaler to a pressurized metered-dose inhaler is not associated with compromised treatment outcomes among patients with asthma.

Source:

J Allergy Clin Immunol Pract 2018; doi:10.1016/j.jaip.2018.09.027

03-10-2018 | Asthma | News | Article

Systemic corticosteroids reduce blood eosinophil counts

Systemic corticosteroid treatment reduces blood eosinophil counts and low levels are maintained for weeks after treatment is discontinued, show real-world data.

Source:

J Asthma 2018; doi:10.1080/02770903.2018.1502301

06-09-2018 | Asthma | News | Article

Single blood eosinophil measure predicts eosinophilic asthma

A single blood eosinophil count could predict persistent eosinophilia in patients with adult-onset asthma, study findings show.

Source:

Respir Med 2018; 141: 81–86

03-09-2018 | Asthma | News | Article

Proportion of asthma patients who could benefit from anti-IL-5 treatment estimated

Researchers estimate that 2% of patients with adult-onset eosinophilic asthma could benefit from treatment involving antibodies against the interleukin-5 pathway.

Source:

J Allergy Clin Immunol Pract 2018; doi:10.1016/j.jaip.2018.05.032

24-07-2018 | Asthma | News | Article

Editor's pick

Proportion of asthma patients who could benefit from anti-IL-5 treatment estimated

Researchers estimate that 2% of patients with adult-onset eosinophilic asthma could benefit from treatment involving antibodies against the interleukin-5 pathway.

Source:

J Allergy Clin Immunol Pract 2018; doi:10.1016/j.jaip.2018.05.032

04-07-2018 | Asthma | News | Article

Editor's pick

Asthma risk prediction score accounts for early treatment response

Researchers have developed a measure for predicting future asthma risk based on patient characteristics and current level of asthma control.

Source:

J Allergy Clin Immunol Pract 2018; Advance online publication

20-06-2018 | Asthma | News | Article

Editor's pick

Good prognosis for patients with mild asthma

Research findings can reassure patients with mild asthma that the long-term prognosis is good, with only a tenth of patients transitioning to more severe disease over 10 years.

Source:

J Allergy Clin Immunol Pract 2018; Advance online publication

08-05-2018 | Asthma | News | Article

Editor's pick

Eosinophilia linked to lung function decline irrespective of asthma symptoms

High blood eosinophil counts are associated with airflow obstruction and lung function decline in patients with asthma, but also in people without respiratory symptoms, population-based study findings show.

Source:

Eur Respir J 2018; Advance online publication

image credits